BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (http://bmjopen.bmj.com/site/about/resources/checklist.pdf) and are provided with free text boxes to elaborate on their assessment. These free text comments are reproduced below.
GENERAL COMMENTS
Is subsample analysis powered to detect differences in CVD outcomes? Will data from children be large enough to detect differences in all variables measured? Uncertain on appropriateness of increasing power by pooling datastatistical opinion needed here.
Will information be sought about what further lifestyle support women have sought/attained/maintained/implemented? It would be desirable to have the same length of follow up rather than 4 to 7 years-is this logistically possible?
Need to describe in more details what is meant by dose-response relationship between diet,activity and later health means. This implies a single unit will be used for diet so that should be elaborated on 3. Figure 1 , line 33-59: I do not get the figures right in the left column. Shouldn't there be 217 subjects in the per-protocol analysis?
REVIEWER

VERSION 1 -AUTHOR RESPONSE
Reviewer 1 (Nick Macklon):
This paper describes an ongoing follow up study designed to ascertain whether an lifestyle intervention prior to conception aimed at reducing BMI in overweight sub fertile women has any longer term benefits on the woman and on her offspring. There is an urgent need for data from intervention trials such as this. > The two main threats to the study are: 1 the relatively minor impact reported in the original paper on BMI and fertility outcomes, suggesting that any longer term effect may not be detected.
In the LIFEstyle study, 38% of the women reached the target weight loss of 5-10%. Previous studies have shown that such a relatively small weight lost can indeed improve cardiometabolic riskfactors*. Furthermore, ( unpublished) data from this same cohort showed that, 6 months after inclusion in the study, the odds ratio for metabolic syndrome was halved in the intervention group (OR = 0.53 (95% CI: 0.33 to 0.85; P < 0.01). Since MetS is related to cardiovascular events later in life, it is indeed worthwhile to investigate the long term cardiometabolic health effect for these women, starting with this 4-7 year follow-up assessment. > Reviewer 1: The lack of data relating to lifestyle, diet and health of the study subjects in the intervening period between the original intervention and the follow up measurements. While subjects will be asked about current and recent lifestyle etc, it is unclear how the intervening period will be addressed.
(Also Reviewer 2: Will information be sought about what further lifestyle support women have sought/attained/maintained/implemented?)
ResponsE: We thank the reviewers for pointing out the fact that we did not mention in this paper that we will retrospectively ask the participants about their weight loss attempts in the 4-7 years after the lifestyle intervention. In the questionnaires, detailed information will be asked about the number of attempts, success of attempts, used methods, kinds of support and amount of weight lost. We have added the sentence 'Information about weight loss attempts in the last 4-7 years' to the Lifestyle measure in Table 3 to let the readers know we will also collect this kind of information.
Reviewer 2 (Annie Anderson):
> Is subsample analysis powered to detect differences in CVD outcomes?
Response: In this follow-up, the analyses are powered on the primary outcome, which is BMI.
> Will data from children be large enough to detect differences in all variables measured?
Response The original LIFEstyle study was powered on the outcomes in the women and since not all women in the LIFEstyle got pregnant (in both study arms, about 55% of the women had a conception within two years after randomization resulting in a live birth), there will be a lower eligible n for the children than for the women. However, we expect the child participant numbers to be high enough to detect a differences in the main outcome child BMI. For some of the other measures, analyses will have an exploratory character, which however seem justified because of the very limited experimental evidence of the long term effects of preconceptional and perinatal interventions.
> Uncertain on appropriateness of increasing power by pooling data -statistical opinion needed here.
Response The reviewer is right that one should be cautious by pooling data of different studies, since it does not always have to lead to an increased power. We included a note about this in our paper and refer to an article of Bangdiwala et al. about this topic (TMB, 2016; 6:228-235).
> It would be desirable to have the same length of follow up rather than 4 to 7 years-is this logistically possible?
Response We agree that studying the women at comparable follow-up duration and the children at comparable ages would have been ideal. Unfortunately, it is logistically not possible to do this because of the duration of the inclusion period into the Lifestyle study and the subsequent 2 year period in which women could conceive, and also due to boundaries of the grant for the WOMB project. This means that, besides the study preparation (including tracing the participants) and dataanalyzing and reporting, there is a relatively limited time window for the actual data collection.
Before analyzing however, we will check if there is a difference between the intervention and control group in follow-up length and we will control for this if necessary. In the child analyses, we will control for age.
> Need to describe in more details what is meant by dose-response relationship between diet, activity and later health means. This implies a single unit will be used for diet so that should be elaborated on
Response We added the following information to the paper (page 6): '…. perform exploratory dose-response analyses in which associations between measures of variation in diet (e.g. fruit/vegetable intake, soft drink intake, snack intake) or physical activity (e.g. weekly moderate to vigorous physical activity) will be linked to outcomes (blood pressure, glucose/lipid levels, weight, child development, health) in both short and long term for women and their children.'
Reviewer 3 (Emelie Stenman):
Dear Dr van de Beek and co-authors, This is a well written and clearly described study protocol. I am looking forward to get information about future results. I have only a few comments:
1. Ethics and safety considerations, line 199: You state that there is no risks on the participants. I miss, however, a short discussion (one sentence) about data handling and confidentiality (there is always a risk of integrity violation).
Response We added the sentence " The data will be handled confidentially and analyzed coded, in compliance with the Dutch Personal Data Protection Act." Response In this phase, we are collecting DNA to enable future GWAS and EWAS studies, without specific a priori hypothesis at this moment in time.
3. Figure 1 , line 33-59: I do not get the figures right in the left column. Shouldn't there be 217 subjects in the per-protocol analysis?
Response: n = 5 participants were 'non-completers' and turned out to be also 'lost to follow up'. We added this information in Figure 1 .
Besides the changes made in response to the reviewers and editors comments, we also took the opportunity to corrected some small things in our paper: Table 2 : changed information about diet data + corrected some flaws -Page 15, Table 3 : added 'sexual health' + information that activity level aspects were also selfreported.
-Page 16, Table 4 : corrected some flaws.
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GENERAL COMMENTS
I remain concerned that the study has a focus on CVD when it will not be powered to assess this. This is not a reason for rejection but further discussion is desirable
VERSION 2 -AUTHOR RESPONSE
In response to the comment of reviewer 2, we added additional text on page 7 (lines 188-190) in which we acknowledge the fact that the original study was not powered to measure cardiovascular outcomes and in which we explain that we did poweranalyses for the follow-up on main outcome BMI as a riskfactor for the development of CVD later in life. We hope that this addition satisfies the request of reviewer 2.
